Sobi Seeks New CEO Who Is Around Sweden, Europe As Business Grows
Executive Summary
Sobi's outgoing US-based CEO says his extended handover will “maintain continuity” as Sweden's rare disease specialist searches for a successor who will "stay closer to home" as it conducts key product launches.
You may also be interested in...
Biogen Hemophilia Spin Out Bioverativ On Track For Early 2017
Bioverativ was unveiled as the name for Biogen’s spin out; an initial Form 10 registration will be filed with SEC later this week.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.